Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on February 3, with a total transaction value of 2.236 billion yuan, highlighting notable trading in specific stocks such as Shanghai Airport, Zijin Mining, and Longjing Environmental Protection [1]. Group 1: Block Trading Activity - A total of 80 stocks underwent block trading, with Shanghai Airport leading at 349 million yuan, followed by Zijin Mining at 274 million yuan and Longjing Environmental Protection at 161 million yuan [1]. - Among the stocks traded, 7 were sold at par value, 2 at a premium, and 71 at a discount, indicating a predominance of discounted trades [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were DeMa Technology at 5.67% and Shen High-Speed at 2.01% [1]. - The stocks with the highest discount rates included Kai Fa Technology at 29.94%, New Wave Shares at 23.56%, and Ai Meike at 23.43% [1]. Group 3: Institutional Buying and Selling - The top institutional buying positions included Shanghai Airport at 349 million yuan, Longxin Zhongke at 116 million yuan, and Xinyuan Shares at 60.575 million yuan [2]. - The leading institutional selling positions were Nanxin Technology at 8.4 million yuan and Guobo Electronics at 4.1784 million yuan [2].

此前，2025年9月10日，深圳国际仲裁院（以下简称"深国仲"）紧急仲裁员曾就达透医疗器械（上海） 有限公司（以下简称"达透公司"）提出的临时措施申请作出《深圳国际仲裁院决定书》（（2025）深国 仲涉外受8781号），决定REGENBiotech,Inc.（以下简称"REGEN公司"）在本案仲裁裁决作出前，不得 自行在中国国内销售AestheFill产品、不得否认达透公司是AestheFill产品在中国国内的独家经销商、不 得拒绝并应继续向达透公司按协议约定供应该产品。 近日，爱美客（300896）发布公告称，1月29日，公司控股子公司REGEN公司收到深圳国际仲裁院作出 的《仲裁庭关于〈撤销临时措施决定申请〉的决定》，仲裁庭决定不再实施由紧急仲裁员于2025年9月 10日作出的《深圳国际仲裁院决定书》临时措施决定。 ...

Group 1 - The medical beauty sector increased by 3.9% on February 3, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 147.57, up 4.56%, and Huaxi Biological at 48.81, up 3.45% [1] Group 2 - The medical beauty sector saw a net inflow of 72.0481 million yuan from main funds, while retail funds experienced a net outflow of 41.6043 million yuan [1] - Ai Meike had a net inflow of 85.9952 million yuan from main funds, but retail funds saw a net outflow of 38.6841 million yuan [2] - Huaxi Biological experienced a net outflow of 10.4367 million yuan from main funds, with a net inflow of 14.2989 million yuan from speculative funds [2]

近日，关于童颜针代理权的仲裁案又迎来新进展。1月30日，爱美客发布公告宣布，1月29日，子公司 REGEN Biotech,Inc.（简称"REGEN公司"）收到深圳国际仲裁院作出的《仲裁庭关于〈撤销临时措施决 定申请〉的决定》，仲裁庭决定不再实施由紧急仲裁员于2025年9月10日作出的前述《深圳国际仲裁院 决定书》。 2025年9月10日，深圳国际仲裁院紧急仲裁员曾就江苏吴中医药发展股份有限公司（简称"江苏吴中"） 控股孙公司达透医疗器械（上海）有限公司（简称"达透公司"）提出的临时措施申请作出《深圳国际仲 裁院决定书》，决定REGEN公司在本案仲裁裁决作出前，不得自行在中国国内销售AestheFill产品、不 得否认达透公司是AestheFill产品在中国国内的独家经销商、不得拒绝并应继续向达透公司按协议约定 供应该产品。自REGEN公司收到上述决定书以来至2026年1月30日，爱美客股价跌幅超28%。不过，上 述《仲裁庭关于〈撤销临时措施决定申请〉的决定》仍不是本案的最终裁决结果，本案尚在审理过程 中。 童颜针代理权陷入"拉锯战" 达透公司于2022年8月与DaceInternationalMedica ...

Core Viewpoint - The medical beauty sector experienced a rise of 2.68% on February 2, with Huaxi Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 2.48% and 2.69% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] - The medical beauty sector stocks showed varied performance, with Huaxi Biological rising by 5.24% to a closing price of 47.18 [1] Group 2: Stock Details - Huaxi Biological (688363) had a trading volume of 118,200 shares and a transaction value of 562 million yuan [1] - Aimei Ke (300896) closed at 141.14, up 1.01%, with a trading volume of 47,500 shares and a transaction value of 683 million yuan [1] - ST Meigu (000615) closed at 3.08, up 0.33%, with a trading volume of 115,100 shares [1] - Jinbo Biological (920982) closed at 214.89, down 2.94%, with a trading volume of 9,949 shares and a transaction value of 217 million yuan [1] Group 3: Fund Flow Analysis - The medical beauty sector saw a net inflow of 100 million yuan from main funds, while retail investors experienced a net outflow of 59.89 million yuan [1] - Aimei Ke had a main fund net inflow of 55.54 million yuan, but a net outflow of 33.36 million yuan from retail investors [2] - Huaxi Biological experienced a main fund net inflow of 44.73 million yuan, with retail investors showing a net outflow of 27.92 million yuan [2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors, including gold and jewelry, offline retail, cosmetics, and medical aesthetics [6][49] Summary by Sections Retail and Social Services Market Review - For the week of January 26 to January 30, the retail and social services indices closed at 2435.34 points and 9283.84 points, respectively, with declines of 4.18% and 3.45% [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Industry Dynamics: HBN and Efficacy Skincare - HBN, established in 2019, is the largest domestic skincare brand in the efficacy segment, focusing on visible results and innovative product strategies [24][25] - The brand's core products, including the "A Retinol" series, have achieved significant sales milestones, with a strong emphasis on scientific validation and consumer trust [29][33] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuang and Chaohongji [6][49] - Offline retail companies adapting to market changes, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Domestic cosmetics brands that emphasize emotional value and safety, recommending brands like Maogeping and Proya [6][50] - Medical aesthetics firms with unique product lines, recommending Meilitiantian Medical Health and Aimeike [6][51]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and suggests focusing on high-quality companies in high-growth sectors [6][49] Summary by Sections Industry Performance Overview - The commercial retail and social services indices reported declines of 4.18% and 3.45% respectively during the week of January 26 to January 30, 2026, ranking 26th and 23rd among 31 primary industries [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Key Industry Developments - HBN, established in 2019, is recognized as the largest domestic skincare brand in the efficacy skincare segment, with a market share of 0.8% in the Chinese improvement skincare market as of 2024 [24][25] - HBN's revenue for the first three quarters of 2025 reached 1.51 billion yuan, a year-on-year increase of 10.2%, with high-efficacy skincare products accounting for 78.6% of total revenue [29] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopuhuangjin and Chaohongji [6][49] - Investment Theme 2: Highlighting retail companies that adapt to emotional value and intelligent trends, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Investment Theme 3: Emphasizing beauty and personal care brands that innovate with emotional value and safe ingredients, recommending brands like Maogeping and Pola [6][50] - Investment Theme 4: Targeting differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Aimeike and Meilitiantian [6][51]

Core Viewpoint - The recent arbitration decision allows REGEN, a subsidiary of Aimeike, to sell AestheFill products in mainland China, but this is not a final ruling, and the ongoing dispute over distribution rights remains uncertain [2][8][20]. Group 1: Arbitration and Market Impact - Aimeike's subsidiary REGEN received a procedural decision from the Shenzhen International Arbitration Court, lifting a temporary measure that previously restricted its sales of AestheFill products in mainland China [2][8]. - Since the initial temporary measure was imposed on September 10, 2025, Aimeike's stock price has dropped nearly 30% [3]. - The arbitration dispute began after Aimeike acquired 85% of REGEN for $190 million in March 2025, leading to REGEN unilaterally terminating its exclusive distribution agreement with Dato Medical [6][8]. Group 2: Business Performance - Aimeike has faced a decline in revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues of 663 million, 636 million, and 566 million yuan, representing year-on-year declines of 17.90%, 25.11%, and 21.27% respectively [11]. - The decline in revenue is attributed to a weakened consumer confidence due to macroeconomic conditions and increased competition in the medical aesthetics industry [14][15]. - Aimeike's main revenue sources, solution and gel injection products, saw significant revenue drops, with total income from these products falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 [15][16]. Group 3: Future Outlook - The AestheFill product, despite its potential, is expected to contribute only around 300 million yuan in annual sales, which may not significantly offset the revenue decline from Aimeike's core products [17]. - The competitive landscape for botulinum toxin products is also challenging, with established players dominating the market, making it difficult for Aimeike to gain market share with newly approved products [18]. - Overall, Aimeike is likely to continue facing significant performance pressures into 2026, despite the short-term positive impact of the arbitration decision [19][20].

Core Viewpoint - The arbitration decision to lift the temporary sales restriction on AestheFill products by REGEN, a subsidiary of Aimeike, is seen as a short-term positive development, but the underlying dispute over distribution rights remains unresolved, indicating potential volatility in the company's stock performance [1][4][14]. Group 1: Arbitration and Sales Rights - REGEN received a decision from the Shenzhen International Arbitration Court on January 29, 2025, which lifted a temporary measure that prohibited the sale of AestheFill products in mainland China [1]. - The temporary measure was initially imposed following REGEN's unilateral termination of its exclusive distribution agreement with Dato Medical, which claimed that Dato had transferred its distribution rights to a related party, violating the agreement [3][4]. - The arbitration decision is procedural and not a final ruling, meaning the dispute over the legality of REGEN's termination of the distribution rights is still ongoing [4]. Group 2: Financial Performance - Aimeike has experienced a decline in both revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues reported at 663 million, 636 million, and 566 million yuan, reflecting year-on-year decreases of 17.90%, 25.11%, and 21.27% respectively [5][6]. - The company's core products, including solution and gel injection products, saw significant revenue drops, with total income from these categories falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 for solution products, and from 6.49 billion yuan to 4.93 billion yuan for gel products [9][10]. - The competitive landscape has intensified, with new entrants in the aesthetic medicine market impacting Aimeike's profit margins and market share [8][9]. Group 3: Future Outlook - The introduction of AestheFill is expected to provide some revenue support, but its annual sales of approximately 300 million yuan may not be sufficient to offset the significant revenue declines from Aimeike's core products [10][11]. - The company faces challenges in gaining market share for newly approved products, such as botulinum toxin, due to established competitors dominating the market [12][13]. - Overall, Aimeike is likely to continue facing substantial performance pressures into 2026, with the recent arbitration decision providing only a temporary boost [14].

Core Viewpoint - The arbitration case involving REGEN, a subsidiary of Aimeike, has seen a significant development with the Shenzhen International Arbitration Court revoking a previous emergency measure that restricted REGEN's operations regarding the AestheFill product in China [1][2] Group 1: Arbitration Developments - On January 29, REGEN received a decision from the Shenzhen International Arbitration Court that revoked the emergency measures imposed on September 10, 2025, which had restricted REGEN from selling AestheFill products in China and recognized Dato Company as the exclusive distributor [1] - The emergency measures had previously mandated that REGEN could not deny Dato Company's exclusive distribution rights and was required to continue supplying products as per the agreement [1] Group 2: REGEN's Counterclaims - REGEN's counterclaims in the arbitration include requests to terminate Dato Company's exclusive agency rights for AestheFill products in mainland China, to annul the related distribution agreements, and to seek compensation for reasonable expenses incurred during the arbitration process [2] - REGEN asserts that Dato Company has committed serious breaches of contract, justifying the termination of the exclusive agency rights and the annulment of the agreements [2] Group 3: Ongoing Legal Proceedings - The arbitration case is still under review, and the impact on Aimeike's current and future profits remains uncertain, contingent on the final arbitration or enforcement results [2] - REGEN has engaged a professional legal team to actively address the arbitration case and will closely monitor its progress [2]